Trulicity is not semaglutide. Trulicity’s active ingredient is dulaglutide, a different medication entirely. The confusion is understandable because both dulaglutide (Trulicity) and semaglutide (sold as Ozempic, Wegovy, and Rybelsus) belong to the same drug class: GLP-1 receptor agonists. They work in a similar way and treat many of the same conditions, but they are chemically distinct drugs made by different manufacturers.
How Trulicity and Semaglutide Are Related
Both dulaglutide and semaglutide mimic a natural gut hormone called GLP-1 that helps regulate blood sugar and appetite. When you eat, your body releases GLP-1 to signal your pancreas to produce insulin and to slow digestion. Both drugs activate the same receptor, which is why they produce similar effects: lower blood sugar, reduced appetite, and weight loss.
Think of them like two different brands of blood pressure medication that happen to work through the same mechanism. They’re relatives, not twins. Dulaglutide is engineered by fusing a modified GLP-1 molecule to a piece of an antibody protein, which keeps it circulating in the body longer. Semaglutide uses a different structural modification to achieve the same goal. The result is that both can be injected once a week, though semaglutide has a slightly longer half-life (about 7 days versus about 5 days for dulaglutide).
Brand Names to Know
Dulaglutide is sold only under one brand name: Trulicity. It’s approved for type 2 diabetes and to reduce cardiovascular risk.
Semaglutide, on the other hand, is sold under multiple brand names. Ozempic is the injectable form for type 2 diabetes. Wegovy is a higher-dose injectable approved for weight management. Rybelsus is an oral tablet form for type 2 diabetes. All three contain semaglutide at different doses or in different formulations.
How They Compare for Blood Sugar and Weight
A major head-to-head trial called SUSTAIN 7 directly compared the two drugs in people with type 2 diabetes. Semaglutide came out ahead on both blood sugar control and weight loss. At the lower doses, semaglutide reduced A1C by 1.5 percentage points compared to 1.1 points for dulaglutide. At the higher doses, semaglutide lowered A1C by 1.8 points versus 1.4 for dulaglutide.
The weight loss gap was even more pronounced. People on the higher dose of semaglutide lost an average of 6.5 kg (about 14 pounds), while those on the higher dose of dulaglutide lost 3.0 kg (about 6.6 pounds). That’s roughly double the weight loss with semaglutide. This difference is one reason semaglutide has received so much attention for weight management, while Trulicity has not been approved for that purpose.
Side Effects Are Surprisingly Similar
Both drugs cause the same general constellation of side effects, primarily nausea, vomiting, diarrhea, and stomach discomfort, especially when first starting or increasing the dose. A large comparative safety study published in the Annals of Internal Medicine found that the rate of serious gastrointestinal complications (including pancreatitis, gallbladder disease, bowel obstruction, and gastroparesis) was essentially the same for both medications. The incidence was roughly 12 events per 1,000 person-years for each drug, with no statistically meaningful difference between them.
This is worth knowing if you’re considering switching from one to the other. A stronger effect on blood sugar and weight does not appear to come with a higher risk of serious gut problems.
Trulicity Dosing
Trulicity is a once-weekly injection that comes in a pre-filled pen. The starting dose is 0.75 mg, which can be increased to 1.5 mg after four weeks. If blood sugar still isn’t well controlled, your dose can continue increasing in 1.5 mg steps, up to a maximum of 4.5 mg per week. Each increase requires at least four weeks at the current dose to let your body adjust and to assess how well it’s working.
Cardiovascular Benefits of Trulicity
One area where Trulicity has strong evidence in its own right is heart health. The REWIND trial, published in The Lancet, followed over 9,900 people with type 2 diabetes for a median of 5.4 years. Participants taking dulaglutide had a 12% lower risk of experiencing a major cardiovascular event (heart attack, stroke, or cardiovascular death) compared to those on placebo. This was a meaningful finding because the trial included a broad population, not just people who already had established heart disease.
Semaglutide has its own cardiovascular outcome data as well, so both drugs offer heart-related benefits. But if your doctor has specifically prescribed Trulicity for cardiovascular risk reduction, it’s supported by a large, long-running trial.
Can You Switch Between Them?
Switching between GLP-1 receptor agonists is common. If Trulicity isn’t providing enough blood sugar control or weight loss, your doctor may suggest moving to semaglutide. If cost or insurance coverage favors one drug over the other, that’s another practical reason to switch. Because they work on the same receptor, the transition is generally straightforward, though you may experience a brief return of nausea as your body adjusts to the new drug’s slightly different profile.
The key takeaway: Trulicity and semaglutide-based medications are close cousins that do similar things, but they are not the same drug. If a prescription says Trulicity, you’re getting dulaglutide, not semaglutide.